StockData
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. (NAMS) stock

NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.39−0.07 (-0.36%)

Close on Nov 17, 2026Market cap $2.32BP/E –Yield –

NewAmsterdam Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

NewAmsterdam Pharma's price to sales ratio was 342.3× on Nov 11, 2026, against 132.6× a year earlier. Over the last 4 years it ranged from 7.1× to 418.7×, with a median of 70.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026342.3×+229.7
2025Dec 31, 2025112.7×+42.1
2024Dec 31, 202470.5×+61.6
2023Dec 29, 20238.9×–

More NewAmsterdam Pharma figures

See a number that looks wrong?